143
Participants
Start Date
June 30, 2011
Primary Completion Date
December 31, 2012
Study Completion Date
June 30, 2013
Cenicriviroc 100 mg
100 mg CVC plus Truvada
Cenicriviroc 200 mg + Truvada
200 mg CVC plus Truvada
Sustiva + Truvada
Sustiva plus Truvada
Clinical Research P.R., Inc., Santurce
Univ. of Puerto Rico - ACTU, San Juan
University of Puerto Rico, School of Medicine, CEMI, San Juan
Bisher Akil, M.D., A Medical Corporation, New York
Aaron Diamond AIDS Research Center, New York
ACRIA, New York
Jacobi Medical Center, New York
Synergy First Medical PLLC, Brooklyn
Erie County Medical Center Corporation, Buffalo
AIDS Care, Rochester
University of Pennsylvania Health System, Philadelphia
Georgetown University Hospital, Washington D.C.
Whitman-Walker Clinic, Washington D.C.
University of North Carolina at Chapel Hill, Chapel Hill
Rosedale Infectious Disease, Huntersville
AIDS Research Consortium of Atlanta, Inc., Atlanta
Chatham County Health Department, Savannah
Orlando Immunology Center, Orlando
Treasure Coast Infectious Disease Consultants, Vero Beach
University of Miami School of Medicine, Miami
Care Resource Inc., Miami
Kinder Medical Group, Miami
Wohlfeiler, Piperato & Associates, LLC, Miami Beach
Therafirst Medical Center, Fort Lauderdale
Gary Richmond, Fort Lauderdale
Triple O Research Institute, PA, West Palm Beach
Health Positive, Safety Harbor
Midway Immunology and Research Center, Ft. Pierce
University of Alabama at Birmingham, Birmingham
Henry Ford Health System, Detroit
North Texas Infectious Diesease Consultants, Dallas
Therapeutic Concepts, Houston
The University of Texas Health Science Center at Houston Medical School, Houston
Southwest Center for HIV / AIDS, Phoenix
AIDS Research Alliance, Los Angeles
Peter J Ruane MD Incorporated, Los Angeles
Oasis Clinic, Los Angeles
Anthony Mills, Los Angeles
AIDS Healthcare Foundation Research Center, Beverly Hills
Pacific Oaks Medical Group, Beverly Hills
Providence Clinical Research, Burbank
Orange Coast Medical Group, Newport Beach
University of California at San Francisco, San Francisco
Quest Clinical Research, San Francisco
Stanford University ACTU, Palo Alto
Community Research Initiative of New England, Boston
ID Care, Hillsborough
University of Cincinnati, Cincinnati
Tobira Therapeutics, Inc.
INDUSTRY